Biogen (BIIB) PT Raised to $177 at Piper Sandler as 'Leqembi Continues to Ramp Well'
Tweet Send to a Friend
Piper Sandler analyst David Amsellem raised the price target on Biogen (NASDAQ: BIIB) to $177.00 (from $157.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
